Last reviewed · How we verify

NCT03195725

How is the Term 'Harm' Being Interpreted and Documented on Hospice DNACPR Forms Following the Tracey Judgement?

Completed Last updated 19 June 2019
What this trial tests

trial testing Review of notes in Cardiopulmonary Resuscitation in 300 participants. Completed in 31 October 2018.

Timeline
24 July 2017
Primary endpoint
31 October 2018
31 October 2018

Quick facts

Lead sponsorThe Royal Wolverhampton Hospitals NHS Trust
StatusCompleted
Study typeOBSERVATIONAL
Enrollment300
Start date24 July 2017
Primary completion31 October 2018
Estimated completion31 October 2018
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

The Royal Wolverhampton Hospitals NHS Trust

Who can join

Eligibility, any sex, with Cardiopulmonary Resuscitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate how discussions surrounding Do Not Attempt Cardiopulmonary Resuscitation (DNACPR) decisions have changed following the Tracey judgement and how "harm" is being defined by clinicians working within specialist palliative care in a hospice setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cardiopulmonary Resuscitation

Currently open trials in the same condition.

Other The Royal Wolverhampton Hospitals NHS Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03195725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing